Managed Healthcare Executive

Facing the practical problems of gene therapy | AMCP Annual 2026

Providers and payers certainly face some formidable challenges when it comes to gene therapy, but it pales in comparison to ...
Fred Hutch

Scientists see foam as starting point of a path to bedside gene therapy

The special properties of methylcellulose foam could make it a vehicle for bedside genetic engineering, according to a proof-of-principle study from bioengineers at Fred Hutch Cancer Center. In the ...
Benzinga.com

FDA Outlines Process To Speed Up Rare Disease Therapy Approvals

The U.S. Food and Drug Administration on Thursday introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare ...
The Peninsula Qatar

Sidra Medicine unveils Qatar’s first advanced gene-editing therapy for blood disorders

A major step forward in treating inherited blood disorders in Qatar Sidra Medicine a member of Qatar Foundation is now ...

AskBio's Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease

Not intended for UK Media Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency ...